Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis01:24

Disorders of Hemostasis

756
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
756

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Venous Intervention in Children: Current Practice and Controversies.

Cardiovascular and interventional radiology·2026
Same author

Association of Patient-Reported Outcomes with Hemophilia A Inhibitor Status and Treatment Product Type.

Journal of clinical medicine·2026
Same author

Inferior Vena Cava Filter Placements and Retrieval in Pediatric Patients: Experience of Four U.S. Pediatric Hospitals.

AJR. American journal of roentgenology·2025
Same author

Endovascular Management of Pediatric Deep Venous Thrombosis.

Seminars in interventional radiology·2025
Same author

Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort.

Blood vessels, thrombosis & hemostasis·2025
Same author

A Naturally Occurring Gain-of-Function Mutation in Factor VIII.

The New England journal of medicine·2025

相关实验视频

Updated: Jun 15, 2025

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

743

在儿科患者的抗凝血药物.

Marilyn J Manco-Johnson1, Aparna Annam2, Timothy Schardt3

  • 1Department of Pediatrics, Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO.

Techniques in vascular and interventional radiology
|August 21, 2024
PubMed
概括

儿童抗血栓剂,包括抗凝固剂和抗血小板药物,越来越多地使用. 本综述详细介绍了它们的机制,安全性和儿童用剂量.

关键词:
青少年 青少年 青少年这是一种抗凝血药物.孩子们的孩子们的孩子们的孩子们.婴儿 婴儿 婴儿 婴儿 婴儿血栓溶解是一种血栓溶解.血栓形成的原因是血栓形成.

更多相关视频

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

519
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

950

相关实验视频

Last Updated: Jun 15, 2025

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

743
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

519
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

950

科学领域:

  • 儿科药理学 儿科药理学
  • 血液学 血液学 血液学
  • 心血管医学 心血管医学

背景情况:

  • 在儿科患者中,抗血栓剂的使用正在增加.
  • 增加对临床试验的纳入,为儿童提供了更多的安全性和有效性数据.
  • 药物包括抗凝剂 (间接,直接的血栓/XA因子抑制剂) 和抗血小板疗法.

研究的目的:

  • 审查儿科患者使用的抗血栓剂.
  • 详细说明作用机制,施用,清除和半衰期.
  • 讨论抗凝治疗中的抗凝治疗.

主要方法:

  • 对当前儿科使用的抗血栓剂的文献综述.
  • 对药物类别,机制,药理动力学和安全性概况的分析.
  • 讨论临床指示和剂量考虑.

主要成果:

  • 有不同的抗血栓类存在,具有独特的特性.
  • 疗效和持续时间取决于指示和患者的稳定性.
  • 药物动力学的变化需要小心对儿童给予剂量.

结论:

  • 了解药物特异性对于安全有效的儿科使用至关重要.
  • 个性化治疗方法对于最佳结果至关重要.
  • 进一步的研究可能会完善儿童的抗血栓策略.